Joseph Haas

Joseph Haas

Senior Writer

Washington, DC

Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.

Latest from Joseph Haas

Lilly’s Q4 Growth Came From More Than Just Tirzepatide

Mounjaro and Zepbound led Lilly’s 45% sales increase, but non-incretin products such as Verzenio and Taltz helped produce 20% growth outside of the incretin portfolio.

Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease

Plus deals involving Vanda/AnaptysBio, OS Therapies/Ayala, Leveragen/Moonlight Bio, Lantheus/Evergreen, Exicure/GPCR, Arrivent/Lepu, InnoCare/KeyMed/Prolium and more.

GH’s Phase IIb Data Show Potential Differentiation In Depression

Seeking to bring its psychedelic candidate to market in treatment-resistant depression, Ireland’s GH sees its drug-device inhalation combo product as offering strong differentiation versus Spravato.

Medicare Part D Redesign To Offset 2025 Growth, AbbVie Says

Expectations for Skyrizi, Rinvoq skyrocket, and while AbbVie expects to return to compound annual growth in the high single digits this year, the Medicare drug benefit redesign will cut revenue by about 4%.

Merck Halts Another Winrevair Study Early

The Phase III HYPERION study in recently diagnosed PAH is ending early due to sotatercept’s strength. Phase III ZENITH similarly stopped early in November.

Helicore Debuts With $65m, Plans For GIP Antagonism In Obesity

Backed by Versant Ventures, Helicore will pursue optimized therapy for underserved obesity patients with an antibody that directly antagonizes GIP and plans for antibody conjugate therapies.